Genetic screening
The Test That Knows Your Future Before You Do
A single vial of blood can now tell you whether your unborn child carries a mutation that won't cause symptoms until they're forty — and medicine has no clean answer for what you're supposed to do with that information.
The Idea
Genetic screening has quietly split into two very different endeavours, and conflating them is where most of the confusion starts. Diagnostic screening looks for a known problem — you have symptoms, a family history, a reason to look. Predictive screening is something stranger: it scans the genome for variants associated with future risk in people who are currently healthy, or not yet born. It is medicine operating in the conditional tense. The recent expansion of polygenic risk scores has sharpened this tension considerably. Rather than hunting for a single high-impact mutation — the BRCA1 variant that sharply raises breast cancer risk, say — polygenic screening aggregates thousands of tiny genetic nudges across the genome into a single score. The score doesn't say 'you will develop heart disease.' It says 'relative to the population, your odds are elevated.' This is probabilistic medicine, and our intuitions about risk are famously bad at handling it. What makes this genuinely interesting is the asymmetry between knowledge and agency. For some conditions, knowing early is transformative — prophylactic surgery, lifestyle changes, surveillance protocols that catch problems when they're still fixable. For others, particularly late-onset neurological conditions, you can know decades in advance and have almost nothing actionable to do with that knowledge. The genome turns out to be less a blueprint than a weather forecast: highly informative in aggregate, maddeningly uncertain for any specific individual.
In the World
In 2012, a researcher named Sergey Brin — co-founder of Google, which is not why this is interesting — disclosed that he had been tested for the LRRK2 mutation, a genetic variant that meaningfully elevates lifetime risk of Parkinson's disease. His mother had Parkinson's. The test came back positive. Brin described his situation not as a diagnosis but as 'a data point' — and poured significant resources into Parkinson's research, funding studies and pushing for the kind of large-scale data-sharing that might eventually produce treatments. The case is instructive because it shows what happens when knowledge, resources, and agency align. Brin could do something with the information. He had the means to fund research and the platform to accelerate it. For most people, a similar result lands very differently: a positive LRRK2 test raises your risk but doesn't determine your fate, there is currently no approved intervention that definitively prevents onset, and the psychological weight of carrying that knowledge for decades is real and largely unsupported by healthcare systems. The Parkinson's example also illustrates the population-level paradox. Brin's disclosure helped normalise genetic testing and drew attention to a disease that was chronically underfunded. The individual burden became a collective benefit — but that trade-off wasn't something Brin was asked to consent to when he spat into a tube.
Why It Matters
Most of us will encounter genetic screening in some form — through a pregnancy, a family diagnosis, a consumer ancestry kit that quietly returns health data, or a GP who starts routinely offering polygenic risk panels as the cost of sequencing continues to fall. The useful mental shift is to stop thinking of a genetic test result as a verdict and start thinking of it as a prior probability — information that updates your picture of the future without closing it. A high polygenic risk score for type 2 diabetes is not a sentence; it's an argument for taking seriously the lifestyle factors you can actually change. But there's a harder question underneath: who should have access to this information, and when? Insurers in some countries have used genetic data to assess risk. Employers theoretically could. Children can be tested for adult-onset conditions before they can consent to knowing. The science moved faster than the ethics, and the frameworks that govern what happens to genomic data — yours, your children's — are still being written. Understanding what these tests actually measure, and what they don't, is the precondition for having any meaningful say in those conversations.
A Question to Ponder
If you could know, with reasonable confidence, one serious health condition you were likely to develop in the next thirty years — would you want to know, and does your answer change depending on whether there's anything you could do about it?
Get a new one of these every morning.
Start learning with Thinkable